News

Enrollment has begun to test additional investigational drugs in the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) programme. ACTIV is a public-private partnership programme to create a coordinated research strategy that prioritizes and speeds development of promising Covid-19 treatments and...

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced initiation of a rolling submission with the European Medicines Agency (EMA) for CVnCoV, the company’s mRNA-based COVID-19 vaccine candidate,...

The UK government has announced an additional £1.5 million of funding to develop a new treatment for gonorrhoea. This investment, on top of £3.5 million committed in 2019, will support the Global Antibiotic Research and Development Partnership (GARDP) in the...

Strides Pharma Science has announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for prednisone tablets USP, 10 mg and 20 mg from the United States Food & Drug Administration (FDA). The...

Pfizer announced that the US FDA has approved the supplemental Biologics License Application (sBLA) for PANZYGA (Immune Globulin Intravenous – ifas 10% Liquid Preparation) to treat adult patients with a rare neurological disease of the peripheral nerves called...

Pfizer Inc. and BioNTech SE announced that the U.S. government has exercised its option for an additional 100 million doses of the Pfizer-BioNTech COVID-19 Vaccine. This brings the total number of doses to be supplied by the companies to...

Exscientia, a leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD). AD is the most...